• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, July 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

New discovery may enhance chemotherapy’s efficiency against leukaemia

Bioengineer by Bioengineer
December 12, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers from Instituto de Medicina Molecular (iMM) João Lobo Antunes have found a mechanism through which certain types of leukaemia resist chemotherapy, thus revealing novel molecular targets that may be used to improve the efficiency of this type of treatment.

In patients with acute myeloid leukaemia, cancer cells resist the effects of chemotherapy, many times resulting in disease recurrence and ultimately death.

The team, led by Sérgio Dias, had previously shown that leukemic cells activate certain molecular signals, namely a cell signalling pathway controlled by the Endothelial Vascular Growth Factor (VEGF), which allow cancer cells to survive despite chemotherapy.

The work, now published in the journal Cancer Research, revealed that a metabolic alteration at the mitochondrial level derived from VEGF's action is involved in chemotherapy resistance. By creating an experimental model of leukaemia in mice whose cancer cells were resistant to chemotherapy the team was able to caracterize these cells' metabolic profile and observed certain modifications at the level of the mitochondria. Using drugs that specifically blocked VEGF's activation, it was possible to revert these mitochondrial modifications and render these cells vulnerable to chemotherapy.

"Our study contributes to an improved understanding of how cellular metabolism plays an important role in the acquisition of resistance to certain therapeutic agents," said Sérgio Dias.

These newly discovered molecular targets will allow the development of therapeutic strategies that may be explored as possible routes to eliminate leukemic cells' resistance to chemotherapy.

###

iMM Lisboa

The Instituto de Medicina Molecular in Lisbon (Portugal) is a private non-profit research institute that offers a vibrant scientific environment where world-class ingenious scientists with an ambitious research portfolio are supported by state-of-the-art technology, aiming to maximize creativity towards discoveries without boundaries. In spite of iMM's young age (created in 2002), several iMM findings, spanning from basic to translational research, are already being applied to improve human health. imm.medicina.ulisboa.pt/en/

Media Contact

Ana de Barros
[email protected]

https://imm.medicina.ulisboa.pt/en/

https://imm.medicina.ulisboa.pt/index.php?cID=2905

Related Journal Article

http://dx.doi.org/10.1158/0008-5472.CAN-17-1166

Share13Tweet8Share2ShareShareShare2

Related Posts

Randomized Phase II Trial Tests Nivolumab Then Nivolumab-Ipilimumab or Docetaxel

July 18, 2026
Necrotizing Enterocolitis: A Paradigm Shift in Understanding

Necrotizing Enterocolitis: A Paradigm Shift in Understanding

July 18, 2026

Clinicians’ Views on Implementing H.O.M.E Mobility Intervention in Acute Care

July 18, 2026

The concealed geometry behind breeding constraints

July 18, 2026
Please login to join discussion

POPULAR NEWS

  • A painless adhesive

    49 shares
    Share 20 Tweet 12
  • Groundbreaking Discovery: New Shark Species Identified for the First Time

    34 shares
    Share 14 Tweet 9
  • 研究人员开发认知工具包,实现阿尔茨海默症早期检测

    50 shares
    Share 20 Tweet 13
  • A varied menu

    51 shares
    Share 22 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Randomized Phase II Trial Tests Nivolumab Then Nivolumab-Ipilimumab or Docetaxel

Necrotizing Enterocolitis: A Paradigm Shift in Understanding

Clinicians’ Views on Implementing H.O.M.E Mobility Intervention in Acute Care

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.